Stem definition | Drug id | CAS RN |
---|---|---|
719 | 23593-75-1 |
Dose | Unit | Route |
---|---|---|
0.10 | g | V |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.07 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 3, 1975 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Macular degeneration | 690.29 | 13.51 | 231 | 12870 | 18677 | 56260289 |
Schizoaffective disorder | 311.16 | 13.51 | 82 | 13019 | 2867 | 56276099 |
Drug level increased | 175.54 | 13.51 | 89 | 13012 | 20636 | 56258330 |
Electrocardiogram QT prolonged | 105.08 | 13.51 | 93 | 13008 | 54495 | 56224471 |
Chronic sinusitis | 73.89 | 13.51 | 37 | 13064 | 8341 | 56270625 |
Vulvovaginal candidiasis | 58.20 | 13.51 | 23 | 13078 | 2963 | 56276003 |
Paraesthesia oral | 57.55 | 13.51 | 38 | 13063 | 14411 | 56264555 |
Procedural pain | 53.46 | 13.51 | 38 | 13063 | 16233 | 56262733 |
Rheumatoid arthritis | 51.25 | 13.51 | 13 | 13088 | 382591 | 55896375 |
Sinus rhythm | 44.46 | 13.51 | 13 | 13088 | 668 | 56278298 |
Oral candidiasis | 42.25 | 13.51 | 35 | 13066 | 18728 | 56260238 |
Eye infection toxoplasmal | 40.16 | 13.51 | 10 | 13091 | 277 | 56278689 |
Vanishing bile duct syndrome | 40.02 | 13.51 | 12 | 13089 | 673 | 56278293 |
Drug interaction | 35.15 | 13.51 | 118 | 12983 | 209637 | 56069329 |
Endocrine ophthalmopathy | 34.50 | 13.51 | 10 | 13091 | 498 | 56278468 |
Swelling of eyelid | 34.42 | 13.51 | 15 | 13086 | 2470 | 56276496 |
Toxic shock syndrome | 32.44 | 13.51 | 10 | 13091 | 616 | 56278350 |
Candida infection | 31.13 | 13.51 | 34 | 13067 | 25633 | 56253333 |
Dyspepsia | 30.62 | 13.51 | 63 | 13038 | 83408 | 56195558 |
Purpura senile | 29.75 | 13.51 | 9 | 13092 | 520 | 56278446 |
Tongue blistering | 27.76 | 13.51 | 11 | 13090 | 1426 | 56277540 |
Febrile neutropenia | 26.91 | 13.51 | 69 | 13032 | 105476 | 56173490 |
Vulvovaginal inflammation | 26.51 | 13.51 | 9 | 13092 | 754 | 56278212 |
Tarsal tunnel syndrome | 25.37 | 13.51 | 8 | 13093 | 531 | 56278435 |
Glossodynia | 25.11 | 13.51 | 3 | 13098 | 152455 | 56126511 |
Swollen tongue | 24.98 | 13.51 | 33 | 13068 | 30291 | 56248675 |
Nasal ulcer | 24.46 | 13.51 | 11 | 13090 | 1951 | 56277015 |
Therapeutic product effect decreased | 24.16 | 13.51 | 5 | 13096 | 169447 | 56109519 |
Eyelid disorder | 23.77 | 13.51 | 10 | 13091 | 1511 | 56277455 |
Angiodermatitis | 22.92 | 13.51 | 5 | 13096 | 76 | 56278890 |
Mean cell haemoglobin increased | 22.35 | 13.51 | 11 | 13090 | 2389 | 56276577 |
Aplastic anaemia | 20.82 | 13.51 | 17 | 13084 | 8911 | 56270055 |
Post viral fatigue syndrome | 20.58 | 13.51 | 6 | 13095 | 305 | 56278661 |
Pelvic pain | 20.41 | 13.51 | 19 | 13082 | 11848 | 56267118 |
Drug ineffective | 20.06 | 13.51 | 312 | 12789 | 918677 | 55360289 |
Dyslipidaemia | 18.96 | 13.51 | 14 | 13087 | 6339 | 56272627 |
Resorption bone increased | 18.81 | 13.51 | 8 | 13093 | 1242 | 56277724 |
Discomfort | 18.59 | 13.51 | 5 | 13096 | 141756 | 56137210 |
Fungal infection | 18.58 | 13.51 | 30 | 13071 | 32963 | 56246003 |
Vestibular disorder | 18.36 | 13.51 | 8 | 13093 | 1317 | 56277649 |
Vaginal infection | 18.15 | 13.51 | 14 | 13087 | 6763 | 56272203 |
Drug intolerance | 18.09 | 13.51 | 21 | 13080 | 264797 | 56014169 |
Stevens-Johnson syndrome | 17.65 | 13.51 | 24 | 13077 | 22639 | 56256327 |
Reperfusion arrhythmia | 17.55 | 13.51 | 5 | 13096 | 234 | 56278732 |
Vulvovaginal discomfort | 17.49 | 13.51 | 9 | 13092 | 2146 | 56276820 |
Toxicity to various agents | 17.37 | 13.51 | 16 | 13085 | 224548 | 56054418 |
Conjunctivitis | 15.41 | 13.51 | 20 | 13081 | 18040 | 56260926 |
Congenital absence of bile ducts | 15.10 | 13.51 | 3 | 13098 | 28 | 56278938 |
Hepatic enzyme increased | 14.75 | 13.51 | 11 | 13090 | 171373 | 56107593 |
Dysuria | 14.73 | 13.51 | 26 | 13075 | 30703 | 56248263 |
SARS-CoV-2 test negative | 14.17 | 13.51 | 5 | 13096 | 470 | 56278496 |
Oedema mouth | 14.14 | 13.51 | 8 | 13093 | 2302 | 56276664 |
Neuropathy peripheral | 13.89 | 13.51 | 54 | 13047 | 102839 | 56176127 |
Stoma site haemorrhage | 13.86 | 13.51 | 6 | 13095 | 972 | 56277994 |
Vulvovaginal pain | 13.85 | 13.51 | 8 | 13093 | 2394 | 56276572 |
Swelling face | 13.60 | 13.51 | 36 | 13065 | 56033 | 56222933 |
Post transplant distal limb syndrome | 13.59 | 13.51 | 4 | 13097 | 210 | 56278756 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Temperature regulation disorder | 25.60 | 15.63 | 8 | 6206 | 614 | 31690516 |
Cellulitis | 21.76 | 15.63 | 36 | 6178 | 47982 | 31643148 |
Hypoglycaemia neonatal | 20.60 | 15.63 | 9 | 6205 | 1773 | 31689357 |
Pulmonary vasculitis | 20.57 | 15.63 | 6 | 6208 | 364 | 31690766 |
Skin infection | 20.15 | 15.63 | 14 | 6200 | 6849 | 31684281 |
Lip haemorrhage | 20.05 | 15.63 | 7 | 6207 | 759 | 31690371 |
Rash pruritic | 19.89 | 15.63 | 24 | 6190 | 23914 | 31667216 |
Accident | 19.07 | 15.63 | 11 | 6203 | 3900 | 31687230 |
Aplastic anaemia | 18.59 | 15.63 | 15 | 6199 | 9188 | 31681942 |
Microtia | 17.58 | 15.63 | 5 | 6209 | 277 | 31690853 |
Congenital umbilical hernia | 17.31 | 15.63 | 5 | 6209 | 293 | 31690837 |
Neuritis | 16.84 | 15.63 | 6 | 6208 | 690 | 31690440 |
Lymphopenia | 16.43 | 15.63 | 17 | 6197 | 14312 | 31676818 |
Fluid replacement | 16.34 | 15.63 | 4 | 6210 | 123 | 31691007 |
Fungal infection | 16.21 | 15.63 | 17 | 6197 | 14534 | 31676596 |
Leukopenia | 15.84 | 15.63 | 35 | 6179 | 57793 | 31633337 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Macular degeneration | 67.52 | 13.37 | 33 | 15523 | 7495 | 70905393 |
Chronic sinusitis | 66.80 | 13.37 | 34 | 15522 | 8417 | 70904471 |
Vulvovaginal candidiasis | 64.74 | 13.37 | 23 | 15533 | 2343 | 70910545 |
Paraesthesia oral | 54.95 | 13.37 | 37 | 15519 | 15380 | 70897508 |
Procedural pain | 47.54 | 13.37 | 36 | 15520 | 17973 | 70894915 |
Oral candidiasis | 47.08 | 13.37 | 41 | 15515 | 24911 | 70887977 |
Aplastic anaemia | 41.02 | 13.37 | 32 | 15524 | 16684 | 70896204 |
Swelling of eyelid | 35.56 | 13.37 | 16 | 15540 | 3016 | 70909872 |
Rheumatoid arthritis | 35.53 | 13.37 | 10 | 15546 | 291795 | 70621093 |
Eye infection toxoplasmal | 34.48 | 13.37 | 10 | 15546 | 530 | 70912358 |
Endocrine ophthalmopathy | 34.14 | 13.37 | 10 | 15546 | 549 | 70912339 |
Vanishing bile duct syndrome | 32.65 | 13.37 | 12 | 15544 | 1347 | 70911541 |
Toxic shock syndrome | 32.10 | 13.37 | 11 | 15545 | 1007 | 70911881 |
Rash pruritic | 29.47 | 13.37 | 51 | 15505 | 62940 | 70849948 |
Dyspepsia | 29.20 | 13.37 | 62 | 15494 | 89015 | 70823873 |
Tongue blistering | 28.84 | 13.37 | 11 | 15545 | 1368 | 70911520 |
Toxicity to various agents | 28.69 | 13.37 | 25 | 15531 | 382147 | 70530741 |
Tarsal tunnel syndrome | 26.35 | 13.37 | 8 | 15548 | 497 | 70912391 |
Purpura senile | 26.26 | 13.37 | 8 | 15548 | 503 | 70912385 |
Candida infection | 26.22 | 13.37 | 35 | 15521 | 34438 | 70878450 |
Nasal ulcer | 25.92 | 13.37 | 11 | 15545 | 1802 | 70911086 |
Swollen tongue | 25.74 | 13.37 | 36 | 15520 | 37010 | 70875878 |
Febrile neutropenia | 24.38 | 13.37 | 99 | 15457 | 204219 | 70708669 |
Pelvic pain | 23.85 | 13.37 | 20 | 15536 | 11540 | 70901348 |
Eyelid disorder | 23.59 | 13.37 | 10 | 15546 | 1634 | 70911254 |
Angiodermatitis | 23.34 | 13.37 | 5 | 15551 | 74 | 70912814 |
Overdose | 22.22 | 13.37 | 5 | 15551 | 169740 | 70743148 |
Stevens-Johnson syndrome | 22.18 | 13.37 | 33 | 15523 | 35874 | 70877014 |
Drug ineffective | 21.44 | 13.37 | 120 | 15436 | 939632 | 69973256 |
Therapeutic product effect decreased | 21.35 | 13.37 | 3 | 15553 | 143015 | 70769873 |
Post viral fatigue syndrome | 20.78 | 13.37 | 6 | 15550 | 313 | 70912575 |
Dyslipidaemia | 20.22 | 13.37 | 17 | 15539 | 9843 | 70903045 |
Gingival swelling | 19.92 | 13.37 | 12 | 15544 | 4117 | 70908771 |
Vaginal infection | 19.60 | 13.37 | 13 | 15543 | 5265 | 70907623 |
Mean cell haemoglobin increased | 18.85 | 13.37 | 11 | 15545 | 3562 | 70909326 |
Pruritus | 18.84 | 13.37 | 135 | 15421 | 345425 | 70567463 |
Resorption bone increased | 18.47 | 13.37 | 8 | 15548 | 1377 | 70911511 |
Fungal infection | 18.39 | 13.37 | 31 | 15525 | 37436 | 70875452 |
Vulvovaginal inflammation | 18.22 | 13.37 | 6 | 15550 | 486 | 70912402 |
Pulmonary vasculitis | 18.21 | 13.37 | 6 | 15550 | 487 | 70912401 |
Urinary tract infection | 17.73 | 13.37 | 104 | 15452 | 248665 | 70664223 |
Vulvovaginal discomfort | 17.11 | 13.37 | 8 | 15548 | 1647 | 70911241 |
Wound complication | 16.95 | 13.37 | 11 | 15545 | 4298 | 70908590 |
Reperfusion arrhythmia | 16.85 | 13.37 | 5 | 15551 | 287 | 70912601 |
Oral mucosal blistering | 16.67 | 13.37 | 12 | 15544 | 5544 | 70907344 |
Lip haemorrhage | 16.35 | 13.37 | 7 | 15549 | 1172 | 70911716 |
Vulvovaginal pain | 16.01 | 13.37 | 8 | 15548 | 1903 | 70910985 |
Plicated tongue | 15.87 | 13.37 | 4 | 15552 | 124 | 70912764 |
Vulvovaginal mycotic infection | 15.23 | 13.37 | 10 | 15546 | 3985 | 70908903 |
Genital rash | 14.74 | 13.37 | 6 | 15550 | 886 | 70912002 |
Vestibular disorder | 14.55 | 13.37 | 8 | 15548 | 2312 | 70910576 |
Swelling face | 14.22 | 13.37 | 38 | 15518 | 63126 | 70849762 |
Kidney transplant rejection | 14.20 | 13.37 | 14 | 15542 | 9947 | 70902941 |
Fluid replacement | 14.02 | 13.37 | 4 | 15552 | 200 | 70912688 |
Eye infection | 14.01 | 13.37 | 14 | 15542 | 10104 | 70902784 |
Accident | 13.79 | 13.37 | 12 | 15544 | 7279 | 70905609 |
Post transplant distal limb syndrome | 13.60 | 13.37 | 5 | 15551 | 562 | 70912326 |
Nephrogenic systemic fibrosis | 13.59 | 13.37 | 11 | 15545 | 6041 | 70906847 |
Vasculitis | 13.57 | 13.37 | 19 | 15537 | 19539 | 70893349 |
Cellulitis | 13.47 | 13.37 | 50 | 15506 | 98878 | 70814010 |
None
Source | Code | Description |
---|---|---|
ATC | A01AB18 | ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment |
ATC | D01AC01 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
ATC | G01AF02 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
FDA CS | M0002083 | Azoles |
FDA EPC | N0000175487 | Azole Antifungal |
CHEBI has role | CHEBI:35441 | antiinfective agents |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:78298 | environmental contaminants |
MeSH PA | D058888 | 14-alpha Demethylase Inhibitors |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000891 | Anti-Infective Agents, Local |
MeSH PA | D000935 | Antifungal Agents |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D065088 | Steroid Synthesis Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tinea pedis | indication | 6020002 | DOID:12403 |
Candidiasis of skin | indication | 49883006 | |
Pityriasis versicolor | indication | 56454009 | DOID:9060 |
Candidal vulvovaginitis | indication | 72605008 | DOID:2272 |
Candidiasis of mouth | indication | 79740000 | DOID:14262 |
Tinea corporis | indication | 84849002 | |
Diaper rash | indication | 91487003 | |
Tinea cruris | indication | 399029005 | |
Prevention of Oropharyngeal Candidiasis | indication | ||
Oropharyngeal Candidiasis | indication | ||
Paronychia | off-label use | 71906005 | DOID:13117 |
Telangiectasia disorder | contraindication | 247479008 | |
Abdominal pain - cause unknown | contraindication | 314212008 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Atrophoderma | contraindication | 399979006 | |
Peripheral vascular disease | contraindication | 400047006 |
Species | Use | Relation |
---|---|---|
Cats | Fungal infections caused by Microsporum canis | Indication |
Cats | Fungal infections caused by Trichophyton mentagrophytes | Indication |
Cats | Otitis externa caused by yeast, Malassezia pachydermatis | Indication |
Dogs | Fungal infections caused by Microsporum canis | Indication |
Dogs | Fungal infections caused by Trichophyton mentagrophytes | Indication |
Product | Applicant | Ingredients |
---|---|---|
Veltrim 1% Dermatologic Cream | Elanco US Inc. | 1 |
Otomax | Intervet Inc. | 3 |
Mometamax Otic Suspension | Intervet Inc. | 3 |
Tri-Otic Ointment | Med-Pharmex Inc. | 3 |
Vetro-Max | Fougera Pharmaceuticals Inc. | 3 |
GBC Ointment | Cronus Pharma Specialities India Private Limited | 3 |
Mometavet | Med-Pharmex Inc. | 3 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.4 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | Ki | 5.19 | DRUG MATRIX | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.38 | DRUG MATRIX | |||||
Nuclear receptor subfamily 1 group I member 3 | Nuclear hormone receptor | ANTAGONIST | IC50 | 6.16 | IUPHAR | ||||
Mu-type opioid receptor | GPCR | Ki | 6.14 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.35 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.39 | DRUG MATRIX | |||||
Adenosine receptor A2a | GPCR | Ki | 5.15 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.35 | DRUG MATRIX | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.52 | CHEMBL | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 7.70 | WOMBAT-PK | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 5.17 | WOMBAT-PK | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.51 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.10 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.00 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.50 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.12 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.24 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.43 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.05 | DRUG MATRIX | |||||
Histamine H1 receptor | GPCR | Ki | 5.47 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.78 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.29 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.68 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 5.83 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 5.27 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.35 | DRUG MATRIX | |||||
Adenosine receptor A1 | GPCR | Ki | 5.11 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.57 | DRUG MATRIX | |||||
Intermediate conductance calcium-activated potassium channel protein 4 | Ion channel | IC50 | 7.15 | CHEMBL | |||||
Nuclear receptor subfamily 1 group I member 2 | Nuclear hormone receptor | WOMBAT-PK | |||||||
D(4) dopamine receptor | GPCR | Ki | 5.16 | DRUG MATRIX | |||||
Carbonic anhydrase 2 | Enzyme | IC50 | 4.52 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.60 | DRUG MATRIX | |||||
Delta-type opioid receptor | GPCR | Ki | 5.76 | DRUG MATRIX | |||||
Acetylcholinesterase | Enzyme | IC50 | 4.71 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
Platelet-activating factor receptor | GPCR | Ki | 4.65 | DRUG MATRIX | |||||
Aromatase | Enzyme | IC50 | 8.74 | CHEMBL | |||||
Cysteinyl leukotriene receptor 1 | GPCR | Ki | 4.78 | CHEMBL | |||||
Epidermal growth factor receptor | Kinase | IC50 | 4.16 | DRUG MATRIX | |||||
Vasopressin V2 receptor | GPCR | IC50 | 5.60 | CHEMBL | |||||
Substance-P receptor | GPCR | Ki | 5.06 | DRUG MATRIX | |||||
Steroid 17-alpha-hydroxylase/17,20 lyase | Enzyme | IC50 | 7.09 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily A member 3 | Ion channel | IC50 | 5.22 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 4.50 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 4.18 | DRUG MATRIX | |||||
Thromboxane-A synthase | Enzyme | IC50 | 7.85 | DRUG MATRIX | |||||
Bile acid receptor | Nuclear hormone receptor | IC50 | 5.49 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | IC50 | 6.89 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.92 | CHEMBL | |||||
Substance-K receptor | GPCR | Ki | 5.47 | DRUG MATRIX | |||||
Transient receptor potential cation channel subfamily M member 2 | Ion channel | IC50 | 5.52 | CHEMBL | |||||
C-C chemokine receptor type 4 | GPCR | IC50 | 5.80 | CHEMBL | |||||
C-X-C chemokine receptor type 1 | GPCR | IC50 | 5.70 | CHEMBL | |||||
Transitional endoplasmic reticulum ATPase | Enzyme | IC50 | 5.85 | CHEMBL | |||||
Malate dehydrogenase cytoplasmic | Enzyme | IC50 | 4.46 | CHEMBL | |||||
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase | Enzyme | IC50 | 6.10 | CHEMBL | |||||
Histamine H2 receptor | GPCR | Ki | 5.29 | DRUG MATRIX | |||||
Lanosterol 14-alpha demethylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 4.70 | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 5.11 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 4.91 | DRUG MATRIX | |||||
Cysteinyl leukotriene receptor 1 | GPCR | Ki | 4.78 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 5.94 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 4.58 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 4.75 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | Kd | 6.70 | CHEMBL | |||||
14-alpha sterol demethylase Cyp51A | Enzyme | Kd | 5.32 | CHEMBL | |||||
14-alpha sterol demethylase | Enzyme | Kd | 6.99 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.23 | CHEMBL | |||||
Mycocyclosin synthase | Enzyme | Kd | 7.14 | CHEMBL | |||||
Putative cytochrome P450 130 | Enzyme | Kd | 4.88 | CHEMBL | |||||
Alpha-chymotrypsin | Enzyme | IC50 | 4.07 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.29 | CHEMBL | |||||
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Enzyme | Ki | 4.46 | CHEMBL |
ID | Source |
---|---|
4018265 | VUID |
N0000146595 | NUI |
D00282 | KEGG_DRUG |
202859 | RXNORM |
4018265 | VANDF |
C0009074 | UMLSCUI |
CHEBI:3764 | CHEBI |
CL6 | PDB_CHEM_ID |
CHEMBL104 | ChEMBL_ID |
DB00257 | DRUGBANK_ID |
D003022 | MESH_DESCRIPTOR_UI |
2812 | PUBCHEM_CID |
2330 | IUPHAR_LIGAND_ID |
2912 | INN_ID |
G07GZ97H65 | UNII |
1284 | MMSL |
4482 | MMSL |
d01236 | MMSL |
002916 | NDDF |
387325003 | SNOMEDCT_US |
5797005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-4146 | LOZENGE | 10 mg | ORAL | ANDA | 14 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-4146 | LOZENGE | 10 mg | ORAL | ANDA | 14 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-8146 | LOZENGE | 10 mg | ORAL | ANDA | 14 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-8146 | LOZENGE | 10 mg | ORAL | ANDA | 14 sections |
Lotrisone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0085-0924 | CREAM | 10 mg | TOPICAL | NDA | 26 sections |
Good Sense Athletes Footantifungal | HUMAN OTC DRUG LABEL | 1 | 0113-0857 | CREAM | 1 g | TOPICAL | OTC monograph final | 13 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0133 | CREAM | 10 mg | TOPICAL | ANDA | 20 sections |
Clotrimazole and Betamethasone Dipropionate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0168-0258 | CREAM | 10 mg | TOPICAL | ANDA | 27 sections |
Clotrimazole and Betamethasone Dipropionate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0168-0370 | LOTION | 10 mg | TOPICAL | ANDA | 20 sections |
Fungicure Liquid Gel | HUMAN OTC DRUG LABEL | 1 | 0295-1363 | LIQUID | 10 mg | TOPICAL | OTC monograph final | 9 sections |
Fungicure Manicure Pedicure Anti Fungal | HUMAN OTC DRUG LABEL | 1 | 0295-6307 | LIQUID | 1 mg | TOPICAL | OTC monograph final | 10 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0363-0220 | CREAM | 10 mg | VAGINAL | ANDA | 16 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0363-0220 | CREAM | 10 mg | VAGINAL | ANDA | 16 sections |
WALGREENS CLOTRIMAZOLE | HUMAN OTC DRUG LABEL | 1 | 0363-1299 | CREAM | 1 g | TOPICAL | OTC monograph final | 11 sections |
athletes foot | HUMAN OTC DRUG LABEL | 1 | 0363-1857 | CREAM | 1 g | TOPICAL | OTC monograph final | 13 sections |
Walgreens Clotrimazole 3 | HUMAN OTC DRUG LABEL | 1 | 0363-2062 | CREAM | 2 g | VAGINAL | NDA | 16 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0363-2105 | CREAM | 10 mg | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
Ringworm | HUMAN OTC DRUG LABEL | 1 | 0363-2107 | CREAM | 10 mg | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
Walgreens Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0363-2109 | CREAM | 10 mg | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0363-3492 | LIQUID | 1 mg | TOPICAL | OTC monograph final | 8 sections |
Walgreens Clotrimazole Antifungal | HUMAN OTC DRUG LABEL | 1 | 0363-7412 | CREAM | 1 g | TOPICAL | OTC monograph final | 11 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0472-0220 | CREAM | 10 mg | VAGINAL | ANDA | 16 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0472-0220 | CREAM | 10 mg | VAGINAL | ANDA | 16 sections |
ClotrimazoleAntifungal | HUMAN OTC DRUG LABEL | 1 | 0472-0350 | CREAM | 10 mg | TOPICAL | OTC monograph final | 13 sections |
Clotrimazole and Betamethasone Dipropionate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0472-0379 | CREAM | 10 mg | TOPICAL | ANDA | 24 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0536-1181 | SOLUTION | 1 g | TOPICAL | OTC monograph final | 13 sections |
Rugby Clotrimazole Antifungal Cream | HUMAN OTC DRUG LABEL | 1 | 0536-1265 | CREAM | 1 g | TOPICAL | OTC monograph final | 12 sections |
RUGBY ANTIFUNGAL CLOTRIMAZOLE | HUMAN OTC DRUG LABEL | 1 | 0536-1272 | CREAM | 0.01 g | TOPICAL | OTC monograph final | 14 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0107 | LOZENGE | 10 mg | ORAL | ANDA | 18 sections |
Major Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0904-7822 | CREAM | 10 mg | TOPICAL | OTC monograph final | 11 sections |